肝素联合前列腺素及复方丹参预防造血干细胞移植术后肝静脉阻塞病的疗效  

Efficacy of prostaglandin,heparin and danshen in prevention of hepatic veno-occlusive disease after hematopoietic stem cell transpIantation

作　　者：郝晶[1] 邓兰[1] 李玉华[1] 

机构地区：[1]南方医科大学珠江医院血液科,广东广州510282

出　　处：《重庆医学》2014年第13期1540-1542,共3页Chongqing medicine

基　　金：国家自然科学基金资助项目(81372249);教育部新世纪优秀人才支持计划基金资助项目(20114433110012);广东省教育厅科技创新基金资助项目(2012KJCX0025)

摘　　要：目的探讨肝素联合前列腺素及复方丹参预防白血病患者造血干细胞移植术(HSCT)后肝静脉阻塞病(HVOD)的疗效。方法回顾性分析2005年1月至2012年12月在该科接受HSCT的72例白血病患者HVOD的发生情况及高危因素。其中,异基因造血干细胞移植(Allo-HSCT)45例,自体造血干细胞移植(Auto-HSCT)27例。所有患者均采用肝素联合前列腺素及复方丹参预防HVOD。结果 72例白血病患者中,2例发生HVOD,发生率为2.7%,其中,重型1例,轻型1例。所有患者均未见明显不良反应。结论肝素联合前列腺素及复方丹参预防白血病患者HSCT术后HVOD安全有效,值得临床推广。Objective To explore the efficacy of prostaglandin combined with heparin and Danshen for the prevention of hepatic veno-occlusive disease（HVOD）after hematopoietic stem cell transplantation（HSCT）in patients with leukemia.Methods The clin-ical data which included incidence and risk factors of HVOD was analyzed in 72 patients with leukemia who received HSCT in our hospital from Jan,2005 to Dec,2012.Among them,45 patients received Allo-HSCT and the others received Auto-HSCT.All pa-tients were treated with prostaglandin combined with heparin and Dansen to prevent HVOD.Results HVOD occurred in 2 cases a-mong 72 patients with leukemia and the incidence was 2.7%,which included one severe case and one mild case.No obvious side effect was observed.Conclusion Combined treatment with prostaglandin,heparin and Danshen is safe and effective for the preven-tion of HVOD after HSCT in patients with leukemia,which can be widely used in clinic.

关 键 词：肝静脉闭塞性疾病 造血干细胞移植 前列腺素 肝素 丹参 

分 类 号：R733.7[医药卫生—肿瘤]